
Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Intrinsic Value
The intrinsic value of one
VRTX
stock under the Base Case scenario is
283.4
USD.
Compared to the current market price of 484.01 USD,
Vertex Pharmaceuticals Inc
is
Overvalued by 41%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Vertex Pharmaceuticals Inc
Fundamental Analysis

Vertex remains heavily dependent on its cystic fibrosis portfolio, and any slowdown in CF sales or an unexpected competitor breakthrough could significantly impact its top line.
Vertex’s CF franchise holds a dominant market position, with new therapies continually maintaining or expanding its share in this high-value therapeutic area.

Revenue & Expenses Breakdown
Vertex Pharmaceuticals Inc
Balance Sheet Decomposition
Vertex Pharmaceuticals Inc
Current Assets | 9.6B |
Cash & Short-Term Investments | 7.7B |
Receivables | 1.6B |
Other Current Assets | 324.8m |
Non-Current Assets | 12.9B |
Long-Term Investments | 5.2B |
PP&E | 2.6B |
Intangibles | 1.9B |
Other Non-Current Assets | 3.3B |
Free Cash Flow Analysis
Vertex Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Vertex Pharmaceuticals Inc
Revenue
|
11B
USD
|
Cost of Revenue
|
-1.5B
USD
|
Gross Profit
|
9.5B
USD
|
Operating Expenses
|
-5.1B
USD
|
Operating Income
|
4.4B
USD
|
Other Expenses
|
-4.9B
USD
|
Net Income
|
-535.6m
USD
|
VRTX Profitability Score
Profitability Due Diligence
Vertex Pharmaceuticals Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Score
Vertex Pharmaceuticals Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
VRTX Solvency Score
Solvency Due Diligence
Vertex Pharmaceuticals Inc's solvency score is 96/100. The higher the solvency score, the more solvent the company is.

Score
Vertex Pharmaceuticals Inc's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VRTX Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
VRTX
is 512.28 USD
with a low forecast of 333.3 USD and a high forecast of 645.75 USD.
Dividends
Current shareholder yield for VRTX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
VRTX
stock under the Base Case scenario is
283.4
USD.
Compared to the current market price of 484.01 USD,
Vertex Pharmaceuticals Inc
is
Overvalued by 41%.